Literature DB >> 21148526

Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin.

Annick Chauty1, Marie-Françoise Ardant, Laurent Marsollier, Gerd Pluschke, Jordi Landier, Ambroise Adeye, Aimé Goundoté, Jane Cottin, Titilola Ladikpo, Therese Ruf, Baohong Ji.   

Abstract

Mycobacterium ulcerans infection is responsible for severe skin lesions in sub-Saharan Africa. We enrolled 30 Beninese patients with Buruli ulcers in a pilot study to evaluate efficacy of an oral chemotherapy using rifampicin plus clarithromycin during an 8-week period. The treatment was well tolerated, and all patients were healed by 12 months after initiation of therapy without relapse.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21148526     DOI： 10.1093/cid/ciq072

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  39 in total

1.  Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Authors:  Marie-Thérèse Ruf; Daniela Schütte; Aurélie Chauffour; Vincent Jarlier; Baohong Ji; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Economic inequality caused by feedbacks between poverty and the dynamics of a rare tropical disease: the case of Buruli ulcer in sub-Saharan Africa.

Authors:  Andrés Garchitorena; Calistus N Ngonghala; Jean-Francois Guegan; Gaëtan Texier; Martine Bellanger; Matthew Bonds; Benjamin Roche
Journal:  Proc Biol Sci       Date:  2015-11-07       Impact factor: 5.349

Review 3.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

4.  [Tropical medicine/tropical dermatology training in Tanzania and Ghana: Personal experience and selected case reports].

Authors:  K Völker
Journal:  Hautarzt       Date:  2015-05       Impact factor: 0.751

5.  Compliance with antimicrobial therapy for buruli ulcer.

Authors:  S Klis; R Kingma; W Tuah; Y Stienstra; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2014-10       Impact factor: 5.191

6.  Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.

Authors:  Daniel P O'Brien; N Deborah Friedman; Aaron Walton; Andrew Hughes; Eugene Athan
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 7.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

8.  Screening of antifungal azole drugs and agrochemicals with an adapted alamarBlue-based assay demonstrates antibacterial activity of croconazole against Mycobacterium ulcerans.

Authors:  Nicole Scherr; Katharina Röltgen; Matthias Witschel; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

9.  Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.

Authors:  N Deborah Friedman; Eugene Athan; Aaron L Walton; Daniel P O'Brien
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 10.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.